Search

Your search keyword '"Serra-Burriel, Miquel"' showing total 297 results
Start Over Author "Serra-Burriel, Miquel"
297 results on '"Serra-Burriel, Miquel"'

1. Drivers of Acceptance of COVID-19 Proximity Tracing Apps in Switzerland: Panel Survey Analysis

Author

von Wyl, Viktor, Höglinger, Marc, Sieber, Chloé, Kaufmann, Marco, Moser, André, Serra-Burriel, Miquel, Ballouz, Tala, Menges, Dominik, Frei, Anja, and Puhan, Milo Alan

Subjects
Public aspects of medicine, RA1-1270
Abstract

BackgroundDigital proximity tracing apps have been released to mitigate the transmission of SARS-CoV-2, the virus known to cause COVID-19. However, it remains unclear how the acceptance and uptake of these apps can be improved. ObjectiveThis study aimed to investigate the coverage of the SwissCovid app and the reasons for its nonuse in Switzerland during a period of increasing incidence of COVID-19 cases. MethodsWe collected data between September 28 and October 8, 2020, via a nationwide online panel survey (COVID-19 Social Monitor, N=1511). We examined sociodemographic and behavioral factors associated with app use by using multivariable logistic regression, whereas reasons for app nonuse were analyzed descriptively. ResultsOverall, 46.5% (703/1511) of the survey participants reported they used the SwissCovid app, which was an increase from 43.9% (662/1508) reported in the previous study wave conducted in July 2020. A higher monthly household income (ie, income >CHF 10,000 or >US $11,000 vs income ≤CHF 6000 or

Published
2021
Full Text
View/download PDF

4. Validation of Adult Spinal Deformity Surgical Outcome Prediction Tools in Adult Symptomatic Lumbar Scoliosis.

Author

Pellise, Ferran, Vila-Casademunt, Alba, Smith, Justin, Bess, Shay, Shaffrey, Christopher, Lenke, Lawrence, Serra-Burriel, Miquel, Bridwell, Keith, Wondra, James, Kelly, Michael, Greenberg, Jacob, Yanik, Elizabeth, and Ames, Christopher

Subjects
Adult, Humans, Quality of Life, Retrospective Studies, Scoliosis, Spinal Fusion, Treatment Outcome
Abstract

STUDY DESIGN: A post hoc analysis. OBJECTIVE: Advances in machine learning (ML) have led to tools offering individualized outcome predictions for adult spinal deformity (ASD). Our objective is to examine the properties of these ASD models in a cohort of adult symptomatic lumbar scoliosis (ASLS) patients. SUMMARY OF BACKGROUND DATA: ML algorithms produce patient-specific probabilities of outcomes, including major complication (MC), reoperation (RO), and readmission (RA) in ASD. External validation of these models is needed. METHODS: Thirty-nine predictive factors (12 demographic, 9 radiographic, 4 health-related quality of life, 14 surgical) were retrieved and entered into web-based prediction models for MC, unplanned RO, and hospital RA. Calculated probabilities were compared with actual event rates. Discrimination and calibration were analyzed using receiver operative characteristic area under the curve (where 0.5=chance, 1=perfect) and calibration curves (Brier scores, where 0.25=chance, 0=perfect). Ninety-five percent confidence intervals are reported. RESULTS: A total of 169 of 187 (90%) surgical patients completed 2-year follow up. The observed rate of MCs was 41.4% with model predictions ranging from 13% to 68% (mean: 38.7%). RO was 20.7% with model predictions ranging from 9% to 54% (mean: 30.1%). Hospital RA was 17.2% with model predictions ranging from 13% to 50% (mean: 28.5%). Model classification for all three outcome measures was better than chance for all [area under the curve=MC 0.6 (0.5-0.7), RA 0.6 (0.5-0.7), RO 0.6 (0.5-0.7)]. Calibration was better than chance for all, though best for RA and RO (Brier Score=MC 0.22, RA 0.16, RO 0.17). CONCLUSIONS: ASD prediction models for MC, RA, and RO performed better than chance in a cohort of adult lumbar scoliosis patients, though the homogeneity of ASLS affected calibration and accuracy. Optimization of models require samples with the breadth of outcomes (0%-100%), supporting the need for continued data collection as personalized prediction models may improve decision-making for the patient and surgeon alike.

Published
2023

5. Correction: LiverScreen project: study protocol for screening for liver fibrosis in the general population in European countries

Author

Graupera, Isabel, Thiele, Maja, Ma, Ann T., Serra-Burriel, Miquel, Pich, Judit, Fabrellas, Núria, Caballeria, Llorenç, de Knegt, Robert J., Grgurevic, Ivica, Reichert, Mathias, Roulot, Dominique, Schattenberg, Jörn M., Pericas, Juan M., Angeli, Paolo, Tsochatzis, Emmanuel A., Guha, Indra Neil, Garcia-Retortillo, Montserrat, Morillas, Rosa M., Hernández, Rosario, Hoyo, Jordi, Fuentes, Matilde, Madir, Anita, Juanola, Adrià, Soria, Anna, Juan, Marta, Carol, Marta, Diaz, Alba, Detlefsen, Sönke, Toran, Pere, Pera, Guillem, Fournier, Céline, Llorca, Anne, Newsome, Phillip N., Manns, Michael, de Koning, Harry J., Serra-Burriel, Feliu, Cucchietti, Fernando, Arslanow, Anita, Korenjak, Marko, van Kleef, Laurens, Falcó, Josep Lluis, Kamath, Patrick S., Karlsen, Tom H., Castera, Laurent, Lammert, Frank, Krag, Aleksander, and Ginès, Pere

Published
2023
Full Text
View/download PDF

6. State-of-the-art reviews predictive modeling in adult spinal deformity: applications of advanced analytics.

Author

Joshi, Rushikesh S, Lau, Darryl, Scheer, Justin K, Serra-Burriel, Miquel, Vila-Casademunt, Alba, Bess, Shay, Smith, Justin S, Pellise, Ferran, and Ames, Christopher P

Subjects
Artificial intelligence, Machine learning, Predictive model, Spinal deformity, Technology, Biomedical Engineering, Clinical Sciences
Abstract

Adult spinal deformity (ASD) is a complex and heterogeneous disease that can severely impact patients' lives. While it is clear that surgical correction can achieve significant improvement of spinopelvic parameters and quality of life measures in adults with spinal deformity, there remains a high risk of complication associated with surgical approaches to adult deformity. Over the past decade, utilization of surgical correction for ASD has increased dramatically as deformity correction techniques have become more refined and widely adopted. Along with this increase in surgical utilization, there has been a massive undertaking by spine surgeons to develop more robust models to predict postoperative outcomes in an effort to mitigate the relatively high complication rates. A large part of this revolution within spine surgery has been the gradual adoption of predictive analytics harnessing artificial intelligence through the use of machine learning algorithms. The development of predictive models to accurately prognosticate patient outcomes following ASD surgery represents a dramatic improvement over prior statistical models which are better suited for finding associations between variables than for their predictive utility. Machine learning models, which offer the ability to make more accurate and reproducible predictions, provide surgeons with a wide array of practical applications from augmenting clinical decision making to more wide-spread public health implications. The inclusion of these advanced computational techniques in spine practices will be paramount for improving the care of patients, by empowering both patients and surgeons to more specifically tailor clinical decisions to address individual health profiles and needs.

Published
2021

7. Real-World Cost-Effectiveness of Pulmonary Vein Isolation for Atrial Fibrillation: A Target Trial Approach

Author

Serra-Burriel, Miquel, Aebersold, Helena, Foster-Witassek, Fabienne, Coslovsky, Michael, Rodondi, Nicolas, Blum, Manuel R., Sticherling, Christian, Moschovitis, Giorgio, Beer, Jürg H., Reichlin, Tobias, Krisai, Philipp, Aeschbacher, Stefanie, Paladini, Rebecca E., Kühne, Michael, Osswald, Stefan, Conen, David, Felder, Stefan, and Schwenkglenks, Matthias

Published
2023
Full Text
View/download PDF

8. Development, validation, and prognostic evaluation of a risk score for long-term liver-related outcomes in the general population: a multicohort study

Author

Alvarez, Marifé, Andersen, Peter, Angeli, Paolo, Ardèvol, Alba, Arslanow, Anita, Beggiato, Luca, Ben Abdesselam, Zahia, Bennett, Lucy, Boutouria, Bajiha, Brocca, Alessandra, Broquetas, M. Teresa, Caballeria, Llorenç, Calvino, Valeria, Camacho, Judith, Capdevila, Aura, Carol, Marta, Castera, Laurent, Cervera, Marta, Cucchietti, Fernando, de Fuentes, Anna, de Knegt, Rob, de Koning, Harry J, Detlefsen, Sonke, Diaz, Alba, Diéguez Bande, José, Esnault, Vanessa, Fabrellas, Núria, Falcó, Josep Lluis, Fernández, Rosa, Fournier, Céline, Fuentes, Matilde, Galle, Peter, García, Edgar, García-Retortillo, Montserrat, Garrido, Esther, Ginès, Pere, Gordillo Medina, Rosa, Gratacós-Ginès, Jordi, Graupera, Isabel, Grgurevic, Ivica, Guha, Indra Neil, Guix, Eva, Hansen, Johanne Kragh, Harris, Rebecca, Hernández Boluda, Elena, Hernández-Ibañez, Rosario, Hoyo, Jordi, Ikram, Arfan, Incicco, Simone, Israelsen, Mads, Juan, Marta, Juanola, Adrià, Kaiser, Ralf, Kamath, Patrick S, Karlsen, Tom H, Kjærgaard, Maria, Korenjak, Marko, Krag, Aleksander, Krawczyk, Marcin, Laboulaye, Philippe, Lambert, Irina, Lammert, Frank, Langkjær Sørensen, Simon, Laserna-Jiménez, Cristina, Lazaro Pi, Sonia, Ledain, Elsa, Levy, Vincent, Lindvig, Katrine Prier, Llorca, Anne, Londoño, Vanessa, Loyer, Guirec, Ma, Ann T., Madir, Anita, Manns, Michael, Marshall, Denise, Martí, M. Lluïsa, Martínez, Sara, Martínez Sala, Ricard, Masa-Font, Roser, Møller Jensen, Jane, Morillas, Rosa M, Muñoz, Laura, Nadal, Ruth, Napoleone, Laura, Navarrete, JM, Newsome, Phillip N, Nielsen, Vibeke, Pérez, Martina, Pericás-Pulido, Juan Manuel, Piano, Salvatore, Pich, Judit, Pose, Elisa, Presas Escobet, Judit, Reichert, Matthias, Riba, Carlota, Roulot, Dominique, Rubio, Ana Belén, Sánchez-Morata, Maria, Schattenberg, Jörn, Serra-Burriel, Miquel, Serra-Burriel, Feliu, Skovborg Just, Louise, Sonneveld, Milan, Soria, Anna, Stern, Christiane, Such, Patricia, Thiele, Maja, Tonon, Marta, Toran, Pere, Torrejón, Antoni, Tsochatzis, Emmanuel A, van Kleef, Laurens, van Wijngaarden, Paulien, Velázquez, Vanessa, Viu, Ana, Weber, Susanne Nicole, Wildsmith, Tracey, Pera, Guillem, Reichert, Mathias, Pericàs, Juan M, Schattenberg, Jörn M, Tsochatztis, Emmanuel A, Garcia-Retortillo, Montserrat, Hernández, Rosario, Expósito, Carmen, Martínez, Alba, Detlefsen, Sönke, Martini, Andrea, Ma, Ann T, Pich, Judith, Bonfill, Eva, Navarrete, J M, Hernáez, Rubén, Allen, Alina, de Knegt, Robert J, and Wong, Vincent Wai-Sun

Published
2023
Full Text
View/download PDF

10. Association of pulmonary vein isolation and major cardiovascular events in patients with atrial fibrillation

Author

Girod, Marc, Coslovsky, Michael, Aeschbacher, Stefanie, Sticherling, Christian, Reichlin, Tobias, Roten, Laurent, Rodondi, Nicolas, Ammann, Peter, Auricchio, Angelo, Moschovitis, Giorgio, Kobza, Richard, Badertscher, Patrick, Knecht, Sven, Krisai, Philipp, Marugg, Andrea, Aebersold, Helena, Hennings, Elisa, Serra-Burriel, Miquel, Schwenkglenks, Matthias, Zuern, Christine S., Bonati, Leo H, Conen, David, Osswald, Stefan, and Kühne, Michael

Published
2022
Full Text
View/download PDF

12. Effectiveness of a Long-term Home-Based Exercise Training Program in Patients With COPD After Pulmonary Rehabilitation: A Multicenter Randomized Controlled Trial

Author

Frei, Anja, Radtke, Thomas, Dalla Lana, Kaba, Brun, Patrick, Sigrist, Thomas, Spielmanns, Marc, Beyer, Swantje, Riegler, Thomas F., Büsching, Gilbert, Spielmanns, Sabine, Kunz, Ramona, Cerini, Tamara, Braun, Julia, Tomonaga, Yuki, Serra-Burriel, Miquel, Polhemus, Ashley, and Puhan, Milo A.

Published
2022
Full Text
View/download PDF

13. Low Accuracy of FIB-4 and NAFLD Fibrosis Scores for Screening for Liver Fibrosis in the Population

Author

Graupera, Isabel, Thiele, Maja, Serra-Burriel, Miquel, Caballeria, Llorenç, Roulot, Dominique, Wong, Grace Lai-Hung, Fabrellas, Núria, Guha, Indra Neil, Arslanow, Anita, Expósito, Carmen, Hernández, Rosario, Aithal, Guruprasad Padur, Galle, Peter R., Pera, Guillem, Wong, Vincent Wai-Sun, Lammert, Frank, Ginès, Pere, Castera, Laurent, and Krag, Aleksander

Published
2022
Full Text
View/download PDF

14. Decompensation in Advanced Nonalcoholic Fatty Liver Disease May Occur at Lower Hepatic Venous Pressure Gradient Levels Than in Patients With Viral Disease

Author

Bassegoda, Octavi, Olivas, Pol, Turco, Laura, Mandorfer, Mattias, Serra-Burriel, Miquel, Tellez, Luis, Kwanten, Wilhelmus, Laroyenne, Alexia, Farcau, Oana, Alvarado, Edilmar, Moga, Lucile, Vuille-Lessard, Elise, Fortea, Jose Ignacio, Ibañez, Luis, Tosetti, Giulia, Vanwolleghem, Thomas, Larrue, Hélène, Burgos-Santamaría, Diego, Stefanescu, Horia, Paternostro, Rafael, Cippitelli, Annalisa, Lens, Sabela, Augustin, Salvador, Llop, Elba, Laleman, Wim, Trebicka, Jonel, Chang, Johannes, Masnou, Helena, Zipprich, Alexander, Miceli, Francesca, Semmler, Georg, Forns, Xavier, Primignani, Massimo, Bañares, Rafael, Puente, Angela, Berzigotti, Annalisa, Rautou, Pierre Emmanuel, Villanueva, Candid, Ginès, Pere, Garcia-Pagan, J.C., Procopet, Bogdan, Bureau, Cristophe, Albillos, Agustin, Francque, Sven, Reiberger, Thomas, Schepis, Filippo, Graupera, Isabel, and Hernandez-Gea, Virginia

Published
2022
Full Text
View/download PDF

15. Surgeons’ risk perception in ASD surgery: The value of objective risk assessment on decision making and patient counselling

Author

Pellisé, Ferran, Vila-Casademunt, Alba, Núñez-Pereira, Susana, Haddad, Sleiman, Smith, Justin S., Kelly, Michael P., Alanay, Ahmet, Shaffrey, Christopher, Pizones, Javier, Yilgor, Çaglar, Obeid, Ibrahim, Burton, Douglas, Kleinstück, Frank, Fekete, Tamas, Bess, Shay, Gupta, Munish, Loibl, Markus, Klineberg, Eric O., Sánchez Pérez-Grueso, Francisco J., Serra-Burriel, Miquel, and Ames, Christopher P.

Published
2022
Full Text
View/download PDF

16. LiverScreen project: study protocol for screening for liver fibrosis in the general population in European countries

Author

Graupera, Isabel, Thiele, Maja, Ma, Ann T., Serra-Burriel, Miquel, Pich, Judit, Fabrellas, Núria, Caballeria, Llorenç, de Knegt, Robert J., Grgurevic, Ivica, Reichert, Mathias, Roulot, Dominique, Schattenberg, Jörn M., Pericas, Juan M., Angeli, Paolo, Tsochatzis, Emmanuel A., Guha, Indra Neil, Garcia-Retortillo, Montserrat, Morillas, Rosa M., Hernández, Rosario, Hoyo, Jordi, Fuentes, Matilde, Madir, Anita, Juanola, Adrià, Soria, Anna, Juan, Marta, Carol, Marta, Diaz, Alba, Detlefsen, Sönke, Toran, Pere, Pera, Guillem, Fournier, Céline, Llorca, Anne, Newsome, Phillip N., Manns, Michael, de Koning, Harry J., Serra-Burriel, Feliu, Cucchietti, Fernando, Arslanow, Anita, Korenjak, Marko, van Kleef, Laurens, Falcó, Josep Lluis, Kamath, Patrick S., Karlsen, Tom H., Castera, Laurent, Lammert, Frank, Krag, Aleksander, and Ginès, Pere

Published
2022
Full Text
View/download PDF

17. Quality of Colonoscopy Is Associated With Adenoma Detection and Postcolonoscopy Colorectal Cancer Prevention in Lynch Syndrome

Author

Sánchez, Ariadna, Roos, Victorine H., Navarro, Matilde, Pineda, Marta, Caballol, Berta, Moreno, Lorena, Carballal, Sabela, Rodríguez-Alonso, Lorena, Ramon y Cajal, Teresa, Llort, Gemma, Piñol, Virginia, López-Fernández, Adrià, Salces, Inmaculada, Picó, Maria Dolores, Rivas, Laura, Bujanda, Luis, Garzon, Marta, Pizarro, Angeles, Martinez de Castro, Eva, López-Arias, Maria Jesus, Poves, Carmen, Garau, Catalina, Rodriguez-Alcalde, Daniel, Herraiz, Maite, Alvarez-Urrutia, Cristina, Dacal, Andres, Carrillo-Palau, Marta, Cid, Lucia, Ponce, Marta, Barreiro-Alonso, Eva, Saperas, Esteban, Aguirre, Elena, Romero, Cristina, Bastiaansen, Barbara, Gonzalez-Acosta, Maribel, Morales-Romero, Blai, Ocaña, Teresa, Rivero-Sánchez, Liseth, Jung, Gerhard, Bessa, Xavier, Cubiella, Joaquin, Jover, Rodrigo, Rodríguez-Moranta, Francisco, Balmaña, Judith, Brunet, Joan, Castells, Antoni, Dekker, Evelien, Capella, Gabriel, Serra-Burriel, Miquel, Moreira, Leticia, Pellise, Maria, and Balaguer, Francesc

Published
2022
Full Text
View/download PDF

19. Time From Approval to Reimbursement of New Drugs: A Comparative Analysis Between the United States, England, Germany, France, and Switzerland (2011–2022).

Author

Glaus, Camille E.G., Serra-Burriel, Miquel, Dusetzina, Stacie B., and Vokinger, Kerstin N.

Subjects
*DRUG approval, *DRUG analysis, *REIMBURSEMENT, *COMPARATIVE studies, *INSURANCE
Abstract

Drug approval enables entry of therapeutic agents into markets, but insurance reimbursement often determines when patients may receive therapy. In this international study (United States, England, Germany, France, Switzerland) examining time from approval to reimbursement, differences in reimbursement processes, and drug coverage were observed. These findings have important policy and safety implications. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. The EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality

Author

Karlsen, Tom H, Sheron, Nick, Zelber-Sagi, Shira, Carrieri, Patrizia, Dusheiko, Geoffrey, Bugianesi, Elisabetta, Pryke, Rachel, Hutchinson, Sharon J, Sangro, Bruno, Martin, Natasha K, Cecchini, Michele, Dirac, Mae Ashworth, Belloni, Annalisa, Serra-Burriel, Miquel, Ponsioen, Cyriel Y, Sheena, Brittney, Lerouge, Alienor, Devaux, Marion, Scott, Nick, Hellard, Margaret, Verkade, Henkjan J, Sturm, Ekkehard, Marchesini, Giulio, Yki-Järvinen, Hannele, Byrne, Chris D, Targher, Giovanni, Tur-Sinai, Aviad, Barrett, Damon, Ninburg, Michael, Reic, Tatjana, Taylor, Alison, Rhodes, Tim, Treloar, Carla, Petersen, Claus, Schramm, Christoph, Flisiak, Robert, Simonova, Marieta Y, Pares, Albert, Johnson, Philip, Cucchetti, Alessandro, Graupera, Isabel, Lionis, Christos, Pose, Elisa, Fabrellas, Núria, Ma, Ann T, Mendive, Juan M, Mazzaferro, Vincenzo, Rutter, Harry, Cortez-Pinto, Helena, Kelly, Deirdre, Burton, Robyn, Lazarus, Jeffrey V, Ginès, Pere, Buti, Maria, Newsome, Philip N, Burra, Patrizia, and Manns, Michael P

Published
2022
Full Text
View/download PDF

24. Comparative Analysis of Drug Shortages in the US and Germany (2016 – 2023).

Author

Nussli, Emanuel, Serra-Burriel, Miquel, and Vokinger, Kerstin N.

Subjects
*CANCER treatment, *INVENTORY shortages, *CARBOPLATIN, *PHARMACEUTICAL industry, *DRUGS, *SPECIALTY hospitals
Abstract

This article analyzes trends in drug shortages in the US and Germany, the largest pharmaceutical market in Europe, between 2016 and 2023. It assesses the commonalities and differences between the countries in terms of active substances in shortage, time duration in shortage, and cyclic trends. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

25. Patients on vitamin K treatment: is switching to direct-acting oral anticoagulation cost-effective? A target trial on a prospective cohort

Author

Aebersold, Helena, primary, Foster-Witassek, Fabienne, additional, Aeschbacher, Stefanie, additional, Beer, Juerg H, additional, Blozik, Eva, additional, Blum, Manuel, additional, Bonati, Leo, additional, Conte, Giulio, additional, Coslovsky, Michael, additional, De Perna, Maria Luisa, additional, Di Valentino, Marcello, additional, Felder, Stefan, additional, Huber, Carola A, additional, Moschovitis, Giorgio, additional, Mueller, Andreas, additional, Paladini, Rebecca E, additional, Reichlin, Tobias, additional, Rodondi, Nicolas, additional, Stauber, Annina, additional, Sticherling, Christian, additional, Szucs, Thomas D, additional, Conen, David, additional, Kuhne, Michael, additional, Osswald, Stefan, additional, Schwenkglenks, Matthias, additional, and Serra-Burriel, Miquel, additional

Published
2024
Full Text
View/download PDF

26. Development, validation, and prognostic evaluation of a risk score for long-term liver-related outcomes in the general population: a multicohort study

Author

Serra-Burriel, Miquel, primary, Juanola, Adrià, additional, Serra-Burriel, Feliu, additional, Thiele, Maja, additional, Graupera, Isabel, additional, Pose, Elisa, additional, Pera, Guillem, additional, Grgurevic, Ivica, additional, Caballeria, Llorenç, additional, Piano, Salvatore, additional, van Kleef, Laurens, additional, Reichert, Mathias, additional, Roulot, Dominique, additional, Pericàs, Juan M, additional, Schattenberg, Jörn M, additional, Tsochatztis, Emmanuel A, additional, Guha, Indra Neil, additional, Garcia-Retortillo, Montserrat, additional, Hernández, Rosario, additional, Hoyo, Jordi, additional, Fuentes, Matilde, additional, Expósito, Carmen, additional, Martínez, Alba, additional, Such, Patricia, additional, Madir, Anita, additional, Detlefsen, Sönke, additional, Tonon, Marta, additional, Martini, Andrea, additional, Ma, Ann T, additional, Pich, Judith, additional, Bonfill, Eva, additional, Juan, Marta, additional, Soria, Anna, additional, Carol, Marta, additional, Gratacós-Ginès, Jordi, additional, Morillas, Rosa M, additional, Toran, Pere, additional, Navarrete, J M, additional, Torrejón, Antoni, additional, Fournier, Céline, additional, Llorca, Anne, additional, Arslanow, Anita, additional, de Koning, Harry J, additional, Cucchietti, Fernando, additional, Manns, Michael, additional, Newsome, Phillip N, additional, Hernáez, Rubén, additional, Allen, Alina, additional, Angeli, Paolo, additional, de Knegt, Robert J, additional, Karlsen, Tom H, additional, Galle, Peter, additional, Wong, Vincent Wai-Sun, additional, Fabrellas, Núria, additional, Castera, Laurent, additional, Krag, Aleksander, additional, Lammert, Frank, additional, Kamath, Patrick S, additional, Ginès, Pere, additional, Alvarez, Marifé, additional, Andersen, Peter, additional, Ardèvol, Alba, additional, Beggiato, Luca, additional, Ben Abdesselam, Zahia, additional, Bennett, Lucy, additional, Boutouria, Bajiha, additional, Brocca, Alessandra, additional, Broquetas, M. Teresa, additional, Calvino, Valeria, additional, Camacho, Judith, additional, Capdevila, Aura, additional, Cervera, Marta, additional, de Fuentes, Anna, additional, de Knegt, Rob, additional, Detlefsen, Sonke, additional, Diaz, Alba, additional, Diéguez Bande, José, additional, Esnault, Vanessa, additional, Falcó, Josep Lluis, additional, Fernández, Rosa, additional, García, Edgar, additional, García-Retortillo, Montserrat, additional, Garrido, Esther, additional, Gordillo Medina, Rosa, additional, Guix, Eva, additional, Hansen, Johanne Kragh, additional, Harris, Rebecca, additional, Hernández Boluda, Elena, additional, Hernández-Ibañez, Rosario, additional, Ikram, Arfan, additional, Incicco, Simone, additional, Israelsen, Mads, additional, Kaiser, Ralf, additional, Kjærgaard, Maria, additional, Korenjak, Marko, additional, Krawczyk, Marcin, additional, Laboulaye, Philippe, additional, Lambert, Irina, additional, Langkjær Sørensen, Simon, additional, Laserna-Jiménez, Cristina, additional, Lazaro Pi, Sonia, additional, Ledain, Elsa, additional, Levy, Vincent, additional, Lindvig, Katrine Prier, additional, Londoño, Vanessa, additional, Loyer, Guirec, additional, Ma, Ann T., additional, Marshall, Denise, additional, Martí, M. Lluïsa, additional, Martínez, Sara, additional, Martínez Sala, Ricard, additional, Masa-Font, Roser, additional, Møller Jensen, Jane, additional, Muñoz, Laura, additional, Nadal, Ruth, additional, Napoleone, Laura, additional, Navarrete, JM, additional, Nielsen, Vibeke, additional, Pérez, Martina, additional, Pericás-Pulido, Juan Manuel, additional, Pich, Judit, additional, Presas Escobet, Judit, additional, Reichert, Matthias, additional, Riba, Carlota, additional, Rubio, Ana Belén, additional, Sánchez-Morata, Maria, additional, Schattenberg, Jörn, additional, Serra-Burriel, Miquel, additional, Skovborg Just, Louise, additional, Sonneveld, Milan, additional, Stern, Christiane, additional, Tsochatzis, Emmanuel A, additional, van Wijngaarden, Paulien, additional, Velázquez, Vanessa, additional, Viu, Ana, additional, Weber, Susanne Nicole, additional, and Wildsmith, Tracey, additional

Published
2023
Full Text
View/download PDF

29. Transient elastography for screening of liver fibrosis: Cost-effectiveness analysis from six prospective cohorts in Europe and Asia

Author

Serra-Burriel, Miquel, Graupera, Isabel, Torán, Pere, Thiele, Maja, Roulot, Dominique, Wai-Sun Wong, Vincent, Neil Guha, Indra, Fabrellas, Núria, Arslanow, Anita, Expósito, Carmen, Hernández, Rosario, Lai-Hung Wong, Grace, Harman, David, Darwish Murad, Sarwa, Krag, Aleksander, Pera, Guillem, Angeli, Paolo, Galle, Peter, Aithal, Guruprasad P., Caballeria, Llorenç, Castera, Laurent, Ginès, Pere, and Lammert, Frank

Published
2019
Full Text
View/download PDF

30. Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database

Author

Dominguez-Valentin, Mev, Sampson, Julian R., Seppälä, Toni T., ten Broeke, Sanne W., Plazzer, John-Paul, Nakken, Sigve, Engel, Christoph, Aretz, Stefan, Jenkins, Mark A., Sunde, Lone, Bernstein, Inge, Capella, Gabriel, Balaguer, Francesc, Thomas, Huw, Evans, D. Gareth, Burn, John, Greenblatt, Marc, Hovig, Eivind, de Vos tot Nederveen Cappel, Wouter H., Sijmons, Rolf H., Bertario, Lucio, Tibiletti, Maria Grazia, Cavestro, Giulia Martina, Lindblom, Annika, Della Valle, Adriana, Lopez-Köstner, Francisco, Gluck, Nathan, Katz, Lior H., Heinimann, Karl, Vaccaro, Carlos A., Büttner, Reinhard, Görgens, Heike, Holinski-Feder, Elke, Morak, Monika, Holzapfel, Stefanie, Hüneburg, Robert, Knebel Doeberitz, Magnus von, Loeffler, Markus, Rahner, Nils, Schackert, Hans K., Steinke-Lange, Verena, Schmiegel, Wolff, Vangala, Deepak, Pylvänäinen, Kirsi, Renkonen-Sinisalo, Laura, Hopper, John L., Win, Aung Ko, Haile, Robert W., Lindor, Noralane M., Gallinger, Steven, Le Marchand, Loïc, Newcomb, Polly A., Figueiredo, Jane C., Thibodeau, Stephen N., Wadt, Karin, Therkildsen, Christina, Okkels, Henrik, Ketabi, Zohreh, Moreira, Leticia, Sánchez, Ariadna, Serra-Burriel, Miquel, Pineda, Marta, Navarro, Matilde, Blanco, Ignacio, Green, Kate, Lalloo, Fiona, Crosbie, Emma J., Hill, James, Denton, Oliver G., Frayling, Ian M., Rødland, Einar Andreas, Vasen, Hans, Mints, Miriam, Neffa, Florencia, Esperon, Patricia, Alvarez, Karin, Kariv, Revital, Rosner, Guy, Pinero, Tamara Alejandra, Gonzalez, María Laura, Kalfayan, Pablo, Tjandra, Douglas, Winship, Ingrid M., Macrae, Finlay, Möslein, Gabriela, Mecklin, Jukka-Pekka, Nielsen, Maartje, and Møller, Pål

Published
2020
Full Text
View/download PDF

31. Accuracy of the Narrow-Band Imaging International Colorectal Endoscopic Classification System in Identification of Deep Invasion in Colorectal Polyps

Author

Muñoz, Guillermo, Peligros, Isabel, Tardio Baiges, Antoni, Elbouayadl, Liliam, Carames, Nuria, Iglesias, Mar, del Carmen, Sofía, González-Lois, Carmen, Núñez, Henar, García Hernández, Sonia, Guerra Pastrián, Laura, López Carreira, Montserrat, Casalots, Álex, Caminoa, Alejandra, Solano, Marina, López-Ibáñez, María, Llaó, Jordina, Estévez, Pamela, Rodríguez-Alcalde, Daniel, Soto, Santiago, Pantaleón, Miguel, Álvarez, Alberto, Zamora Martínez, Tomás, Pascual, Juan Manuel, Ducóns, Julio, García-Lledó, Javier, Porta, Francesc, Hernández, Vicent, Cubiella, Joaquin, Riu, Faust, Simón, Miguel Ángel, Martínez, David, Seoane, Agustín, Gomollón, Fernando, Cid, Lucía, Sostres, Carlos, Domínguez, Fulgencio, Macenlle, Ramiro Manuel, de la Revilla, Juan, Isava, Álvaro, Campo, Rafael, de la Poza, Gema, Martínez, Alfonso, Quintas, Paola, Sánchez, Eloy, Foruny, Jose Ramón, Marín, Eva, Martínez, José Luis, Castro, Maria Inés, González, Juan Ángel, Llop, Elba, Martín, Eduardo, Rey, Rafael, Sort, Pau, Montesinos, Jesús, Fornells, Marta, Ascon, Nadia, Puig, Ignasi, López-Cerón, María, Arnau, Anna, Rosiñol, Òria, Cuatrecasas, Miriam, Herreros-de-Tejada, Alberto, Ferrández, Ángel, Serra-Burriel, Miquel, Nogales, Óscar, Vida, Francesc, de Castro, Luisa, López-Vicente, Jorge, Vega, Pablo, Álvarez-González, Marco A., González-Santiago, Jesús, Hernández-Conde, Marta, Díez-Redondo, Pilar, Rivero-Sánchez, Liseth, Gimeno-García, Antonio Z., Burgos, Aurora, García-Alonso, Francisco Javier, Bustamante-Balén, Marco, Martínez-Bauer, Eva, Peñas, Beatriz, and Pellise, Maria

Published
2019
Full Text
View/download PDF

33. Estimating the cost impact of atrial fibrillation using a prospective cohort study and population-based controls

Author

Aebersold, Helena, primary, Foster-Witassek, Fabienne, additional, Serra-Burriel, Miquel, additional, Brüngger, Beat, additional, Aeschbacher, Stefanie, additional, Beer, Jürg-Hans, additional, Blozik, Eva, additional, Blum, Manuel, additional, Bonati, Leo, additional, Conen, David, additional, Conte, Giulio, additional, Felder, Stefan, additional, Huber, Carola, additional, Kuehne, Michael, additional, Moschovitis, Giorgio, additional, Mueller, Andreas, additional, Paladini, Rebecca E, additional, Reichlin, Tobias, additional, Rodondi, Nicolas, additional, Springer, Anne, additional, Stauber, Annina, additional, Sticherling, Christian, additional, Szucs, Thomas, additional, Osswald, Stefan, additional, and Schwenkglenks, Matthias, additional

Published
2023
Full Text
View/download PDF

36. Colon capsule endoscopy versus CT colonography in FIT-positive colorectal cancer screening subjects: a prospective randomised trial—the VICOCA study

Author

González-Suárez, Begoña, Pagés, Mario, Araujo, Isis Karina, Romero, Cristina, Rodríguez de Miguel, Cristina, Ayuso, Juan Ramón, Pozo, Àngels, Vila-Casadesús, Maria, Serradesanferm, Anna, Ginès, Àngels, Fernández-Esparrach, Glòria, Pellisé, Maria, López-Cerón, María, Flores, David, Córdova, Henry, Sendino, Oriol, Grau, Jaume, Llach, Josep, Serra-Burriel, Miquel, Cárdenas, Andrés, Balaguer, Francesc, and Castells, Antoni

Published
2020
Full Text
View/download PDF

37. Patient clusters and cost trajectories in the Swiss Atrial Fibrillation cohort

Author

Aebersold, Helena, Serra-Burriel, Miquel, Foster-Wittassek, Fabienne, Moschovitis, Giorgio, Aeschbacher, Stefanie, Auricchio, Angelo, Beer, Jürg Hans, Blozik, Eva, Bonati, Leo H, Conen, David, Felder, Stefan, Huber, Carola A, Kuehne, Michael, Mueller, Andreas, Oberle, Jolanda, Paladini, Rebecca E, Reichlin, Tobias, Rodondi, Nicolas, Springer, Anne, Stauber, Annina, Sticherling, Christian, Szucs, Thomas D, Osswald, Stefan, Schwenkglenks, Matthias, University of Zurich, and Aebersold, Helena

Subjects
360 Soziale Probleme, Sozialdienste, 610 Medicine & health, 10060 Epidemiology, Biostatistics and Prevention Institute (EBPI), 610 Medizin und Gesundheit, Cardiology and Cardiovascular Medicine, 2705 Cardiology and Cardiovascular Medicine
Abstract

ObjectiveEvidence on long-term costs of atrial fibrillation (AF) and associated factors is scarce. As part of the Swiss-AF prospective cohort study, we aimed to characterise AF costs and their development over time, and to assess specific patient clusters and their cost trajectories.MethodsSwiss-AF enrolled 2415 patients with variable duration of AF between 2014 and 2017. Patient clusters were identified using hierarchical cluster analysis of baseline characteristics. Ongoing yearly follow-ups include health insurance clinical and claims data. An algorithm was developed to adjudicate costs to AF and related complications.ResultsA subpopulation of 1024 Swiss-AF patients with available claims data was followed up for a median (IQR) of 3.24 (1.09) years. Average yearly AF-adjudicated costs amounted to SFr5679 (€5163), remaining stable across the observation period. AF-adjudicated costs consisted mainly of inpatient and outpatient AF treatment costs (SFr4078; €3707), followed by costs of bleeding (SFr696; €633) and heart failure (SFr494; €449). Hierarchical analysis identified three patient clusters: cardiovascular (CV; N=253 with claims), isolated-symptomatic (IS; N=586) and severely morbid without cardiovascular disease (SM; N=185). The CV cluster and SM cluster depicted similarly high costs across all cost outcomes; IS patients accrued the lowest costs.ConclusionOur results highlight three well-defined patient clusters with specific costs that could be used for stratification in both clinical and economic studies. Patient characteristics associated with adjudicated costs as well as cost trajectories may enable an early understanding of the magnitude of upcoming AF-related healthcare costs.

Published
2022

38. Utilization of Predictive Modeling to Determine Episode of Care Costs and to Accurately Identify Catastrophic Cost Nonwarranty Outlier Patients in Adult Spinal Deformity Surgery: A Step Toward Bundled Payments and Risk Sharing

Author

Ames, Christopher P., Smith, Justin S., Gum, Jeffrey L., Kelly, Michael, Vila-Casademunt, Alba, Burton, Douglas C., Hostin, Richard, Yeramaneni, Samrat, Lafage, Virginie, Schwab, Frank J., Shaffrey, Christopher I., Bess, Shay, Pellisé, Ferran, and Serra-Burriel, Miquel

Published
2020
Full Text
View/download PDF

39. Development of Deployable Predictive Models for Minimal Clinically Important Difference Achievement Across the Commonly Used Health-Related Quality of Life Instruments in Adult Spinal Deformity Surgery

Author

Ames, Christopher P., Smith, Justin S., Pellisé, Ferran, Kelly, Michael P., Gum, Jeffrey L., Alanay, Ahmet, Acaroğlu, Emre, Pérez-Grueso, Francisco Javier Sánchez, Kleinstück, Frank S., Obeid, Ibrahim, Vila-Casademunt, Alba, Burton, Douglas C., Lafage, Virginie, Schwab, Frank J., Shaffrey, Christopher I., Bess, Shay, and Serra-Burriel, Miquel

Published
2019
Full Text
View/download PDF

40. Delivering Safe Surgical Care While Simultaneously Caring for Patients With COVID-19; Assessment of Patient Selection, Volume and Outcomes in a Tertiary Care Hospital

Author

Domenghino, Anja, primary, Staiger, Roxane Diane, additional, Abbassi, Fariba, additional, Serra-Burriel, Miquel, additional, Leutwyler, Kim, additional, Aeby, Guillaume, additional, Turina, Matthias, additional, Gutschow, Christian Alexander, additional, Clavien, Pierre-Alain, additional, and Puhan, Milo Alan, additional

Published
2023
Full Text
View/download PDF

42. Nationwide indoor smoking ban and impact on smoking behaviour and lung function:a two-population natural experiment

Author

Strassmann, Alexandra, Colak, Yunus, Serra-Burriel, Miquel, Nordestgaard, Borge G., Turk, Alexander, Afzal, Shoaib, Puhan, Milo A, Strassmann, Alexandra, Colak, Yunus, Serra-Burriel, Miquel, Nordestgaard, Borge G., Turk, Alexander, Afzal, Shoaib, and Puhan, Milo A

Abstract

Introduction Many countries have implemented indoor smoking bans over the past two decades. Although smoking bans have been shown to reduce cardiovascular outcomes, little is known about their impact on respiratory health. This study investigated the impact of a nationwide indoor smoking ban on smoking behaviour and lung function. Methods We used repeated cross-sectional data from two large cohorts of the general population comprising 31 807 Swiss and 62 093 Danish adults. We compared associations between smoking ban and smoking prevalence and prebronchodilator lung function trends in Denmark (indoor smoking ban introduced in 2007) and Switzerland (indoor smoking ban introduced in 2010) from 2005 to 2010 using a quasi-experimental study design. We performed difference-in-difference analyses with linear regression models adjusted for age, sex, weight and height. Results Denmark had a stronger decrease in active smokers compared with Switzerland. Also, forced expiratory volume in the first second was higher in Danish adults than in Swiss adults: 26 mL (95% CI 2.4 to 49) 1 year, 88 mL (65 to 112) 2 years, and 74 mL (51 to 98) 3 years after smoking ban implementation. Correspondingly, forced vital capacity was higher in Danish adults compared with Swiss adults (80 mL (50 to 109) after 1 year and 126 mL (97 to 155) after two and 3 years). Improvements were observed in both never-smokers and ever-smokers, most pronounced in ever-smokers. Conclusions Nationwide indoor smoking ban is associated with less smoking and improved lung function in the general population. Implementing an indoor smoking ban can improve lung function by influencing smoking behaviour and reducing secondhand smoke.

Published
2023

43. The cancer premium – explaining differences in prices for cancer vs non-cancer drugs with efficacy and epidemiological endpoints in the US, Germany, and Switzerland: a cross sectional study

Author

Vokinger, Kerstin N; https://orcid.org/0000-0002-6997-7384, Serra-Burriel, Miquel, Laube, Yannic, Perényi, Gellért, Mitchell, Aaron P, Vokinger, Kerstin N; https://orcid.org/0000-0002-6997-7384, Serra-Burriel, Miquel, Laube, Yannic, Perényi, Gellért, and Mitchell, Aaron P

Abstract

Background: High treatment prices of new cancer drugs are a global public health challenge to patients and healthcare systems. Policymakers in the US and Europe are debating reforms to drug pricing. The objective of this study was to assess whether drug efficacy or epidemiological characteristics (prevalence, incidence, mortality) explain the gap in treatment prices between cancer and non-cancer drugs in the US, Germany, and Switzerland. Methods: This cross-sectional study identified all new drugs approved in the US, Germany, and Switzerland between 2011 and 2020. Drug efficacy was extracted from pivotal trials, drug prices from public and commercial databases, and epidemiological characteristics from the Global Burden of Disease (GBD) 2019 study. We used regression models to explain drug prices with drug efficacy and epidemiological characteristics (prevalence, incidence, mortality). Findings: The cohort included 181 drugs, including 68 (37.5%) drugs approved for treatment of cancer. A significant negative correlation was found between incidence/prevalence and treatment prices, and a significant positive correlation was observed between mortality and treatment prices for both, cancer and non-cancer drugs. A significant association between relative drug efficacy and treatment prices of drugs was observed, however, less pronounced for cancer drugs. Our regression estimates indicated that after adjusting for efficacy and epidemiological characteristics, cancer drugs were on average approximately three times more expensive compared to non-cancer drugs in all three countries, indicating a cancer premium; i.e., treatment prices of cancer drugs were on average USD 74,412 (95% CI [62,810; 86,015]) more expensive in the US compared to non-cancer drugs, USD 37,770 (95% CI [26,175; 49,367]) more expensive in Germany, and USD 32,801 (95% CI [27,048; 38,555]) more expensive in Switzerland. Our model explained 72% of the variance in observed prices (R2). Interpretation: Drug pri

Published
2023

44. Delivering Safe Surgical Care While Simultaneously Caring for Patients With COVID-19; Assessment of Patient Selection, Volume and Outcomes in a Tertiary Care Hospital

Author

Domenghino, Anja; https://orcid.org/0000-0002-8617-409X, Staiger, Roxane Diane, Abbassi, Fariba, Serra-Burriel, Miquel; https://orcid.org/0000-0001-8595-1224, Leutwyler, Kim, Aeby, Guillaume, Turina, Matthias; https://orcid.org/0000-0002-1040-3511, Gutschow, Christian Alexander, Clavien, Pierre-Alain; https://orcid.org/0000-0002-9916-7905, Puhan, Milo Alan; https://orcid.org/0000-0001-7284-1317, Domenghino, Anja; https://orcid.org/0000-0002-8617-409X, Staiger, Roxane Diane, Abbassi, Fariba, Serra-Burriel, Miquel; https://orcid.org/0000-0001-8595-1224, Leutwyler, Kim, Aeby, Guillaume, Turina, Matthias; https://orcid.org/0000-0002-1040-3511, Gutschow, Christian Alexander, Clavien, Pierre-Alain; https://orcid.org/0000-0002-9916-7905, and Puhan, Milo Alan; https://orcid.org/0000-0001-7284-1317

Abstract

Objectives: Compare patient selection and postoperative outcomes after surgical treatment for gastrointestinal disorders before and during the SARS-CoV-2 pandemic. Methods: We assessed gastrointestinal surgeries conducted at a tertiary center from 2017-2021 for differences in patient populations and procedures before (up to February 2020) and during the pandemic (March 2020 to December 2021). We analyzed mortality, Intensive Care Unit (ICU) length of stay, admission to ICU and postoperative complications for complex procedures using descriptive statistics and regression models. Results: 7309 procedures were analyzed, showing a caseload reduction in March and October 2020, but no statistical evidence for fewer overall procedures overall. Population characteristics differed with lower Body Mass Indices in 2020 and 2021, more patients smoking and with diabetes treated in 2020. There was no increased mortality, ICU length of stay and in 1,144 complex procedures assessed low overall morbidity at 90 days postoperative. Conclusion: Delivering surgical care while treating patients for COVID-19 in the same hospital was safe. Healthcare officials should consider continuing surgical care during future health crises as consequences of limiting surgical treatment for gastrointestinal disorders may be fatal for patients.

Published
2023

45. Longitudinal Changes in Health-Related Quality of Life in Patients With Atrial Fibrillation

Author

Foster-Witassek, Fabienne; https://orcid.org/0000-0002-1631-5838, Aebersold, Helena; https://orcid.org/0000-0002-4418-9904, Aeschbacher, Stefanie; https://orcid.org/0000-0001-8134-2421, Ammann, Peter, Beer, Jürg H; https://orcid.org/0000-0002-7199-0406, Blozik, Eva; https://orcid.org/0009-0004-6773-4487, Bonati, Leo H; https://orcid.org/0000-0003-1163-8133, Cattaneo, Mattia, Coslovsky, Michael; https://orcid.org/0000-0001-7678-7354, Felder, Stefan; https://orcid.org/0000-0002-5029-7274, Moschovitis, Giorgio; https://orcid.org/0000-0002-4043-8061, Müller, Andreas; https://orcid.org/0000-0001-7845-9012, Netzer, Seraina, Paladini, Rebecca E; https://orcid.org/0000-0002-4502-1978, Reichlin, Tobias; https://orcid.org/0000-0002-7197-8415, Rodondi, Nicolas; https://orcid.org/0000-0001-9083-6896, Stauber, Annina; https://orcid.org/0009-0008-6006-8177, Sticherling, Christian; https://orcid.org/0000-0001-8428-7050, Szucs, Thomas; https://orcid.org/0000-0003-0195-3316, Conen, David; https://orcid.org/0000-0002-2459-5251, Kühne, Michael; https://orcid.org/0000-0002-2937-3711, Osswald, Stefan; https://orcid.org/0000-0002-9240-6731, Serra-Burriel, Miquel; https://orcid.org/0000-0001-8595-1224, Schwenkglenks, Matthias; https://orcid.org/0000-0001-7217-1173, Foster-Witassek, Fabienne; https://orcid.org/0000-0002-1631-5838, Aebersold, Helena; https://orcid.org/0000-0002-4418-9904, Aeschbacher, Stefanie; https://orcid.org/0000-0001-8134-2421, Ammann, Peter, Beer, Jürg H; https://orcid.org/0000-0002-7199-0406, Blozik, Eva; https://orcid.org/0009-0004-6773-4487, Bonati, Leo H; https://orcid.org/0000-0003-1163-8133, Cattaneo, Mattia, Coslovsky, Michael; https://orcid.org/0000-0001-7678-7354, Felder, Stefan; https://orcid.org/0000-0002-5029-7274, Moschovitis, Giorgio; https://orcid.org/0000-0002-4043-8061, Müller, Andreas; https://orcid.org/0000-0001-7845-9012, Netzer, Seraina, Paladini, Rebecca E; https://orcid.org/0000-0002-4502-1978, Reichlin, Tobias; https://orcid.org/0000-0002-7197-8415, Rodondi, Nicolas; https://orcid.org/0000-0001-9083-6896, Stauber, Annina; https://orcid.org/0009-0008-6006-8177, Sticherling, Christian; https://orcid.org/0000-0001-8428-7050, Szucs, Thomas; https://orcid.org/0000-0003-0195-3316, Conen, David; https://orcid.org/0000-0002-2459-5251, Kühne, Michael; https://orcid.org/0000-0002-2937-3711, Osswald, Stefan; https://orcid.org/0000-0002-9240-6731, Serra-Burriel, Miquel; https://orcid.org/0000-0001-8595-1224, and Schwenkglenks, Matthias; https://orcid.org/0000-0001-7217-1173

Abstract

Background: Optimizing health-related quality of life (HRQoL) is an important aim of atrial fibrillation (AF) treatment. Little is known about patients' long-term HRQoL trajectories and the impact of patient and disease characteristics. The aim of this study was to describe HRQoL trajectories in an observational AF study population and in clusters of patients with similar patient and disease characteristics. Methods and Results: We used 5-year follow-up data from the Swiss-Atrial Fibrillation prospective cohort, which enrolled 2415 patients with prevalent AF from 2014 to 2017. HRQoL data, collected yearly, comprised EuroQoL-5 dimension utilities and EuroQoL visual analog scale scores. Patient clusters with similar characteristics at enrollment were identified using hierarchical clustering. HRQoL trajectories were analyzed descriptively and with inverse probability-weighted regressions. Effects of postbaseline clinical events were additionally assessed using time-shifted event variables. Among 2412 (99.9%) patients with available baseline HRQoL, 3 clusters of patients with AF were identified, which we characterized as follows: "cardiovascular dominated," "isolated symptomatic," and "severely morbid without cardiovascular disease." Utilities and EuroQoL visual analog scale scores remained stable over time for the full population and the clusters; isolated symptomatic patients showed higher levels of HRQoL. Utilities were reduced after occurrences of stroke, hospitalization for heart failure, and bleeding, by -0.12 (95% CI, -0.18 to -0.06), -0.10 (95% CI, -0.13 to -0.08), and -0.06 (95% CI, -0.08 to -0.04), respectively, on a 0 to 1 utility scale. Utility of surviving patients returned to preevent levels 4 years after heart failure hospitalization; 3 years after bleeding; and 1 year after stroke. Conclusions: In patients with prevalent AF, HRQoL was stable over time, irrespective of baseline patient characteristics. Clinical events of hospitalization for heart failure

Published
2023

46. Estimating the cost impact of atrial fibrillation using a prospective cohort study and population-based controls

Author

Aebersold, Helena; https://orcid.org/0000-0002-4418-9904, Foster-Witassek, Fabienne; https://orcid.org/0000-0002-1631-5838, Serra-Burriel, Miquel; https://orcid.org/0000-0001-8595-1224, Brüngger, Beat; https://orcid.org/0000-0001-6173-5375, Aeschbacher, Stefanie; https://orcid.org/0000-0001-8134-2421, Beer, Jürg-Hans; https://orcid.org/0000-0002-7199-0406, Blozik, Eva; https://orcid.org/0000-0002-0620-6873, Blum, Manuel, Bonati, Leo, Conen, David; https://orcid.org/0000-0002-2459-5251, Conte, Giulio, Felder, Stefan; https://orcid.org/0000-0002-5029-7274, Huber, Carola; https://orcid.org/0000-0002-2469-0435, Kuehne, Michael, Moschovitis, Giorgio; https://orcid.org/0000-0002-4043-8061, Mueller, Andreas, Paladini, Rebecca E; https://orcid.org/0000-0002-4502-1978, Reichlin, Tobias; https://orcid.org/0000-0002-7197-8415, Rodondi, Nicolas; https://orcid.org/0000-0001-9083-6896, Springer, Anne; https://orcid.org/0000-0002-4829-1041, Stauber, Annina; https://orcid.org/0009-0008-6006-8177, Sticherling, Christian; https://orcid.org/0000-0001-8428-7050, Szucs, Thomas; https://orcid.org/0000-0003-0195-3316, Osswald, Stefan; https://orcid.org/0000-0002-9240-6731, Schwenkglenks, Matthias; https://orcid.org/0000-0001-7217-1173, Aebersold, Helena; https://orcid.org/0000-0002-4418-9904, Foster-Witassek, Fabienne; https://orcid.org/0000-0002-1631-5838, Serra-Burriel, Miquel; https://orcid.org/0000-0001-8595-1224, Brüngger, Beat; https://orcid.org/0000-0001-6173-5375, Aeschbacher, Stefanie; https://orcid.org/0000-0001-8134-2421, Beer, Jürg-Hans; https://orcid.org/0000-0002-7199-0406, Blozik, Eva; https://orcid.org/0000-0002-0620-6873, Blum, Manuel, Bonati, Leo, Conen, David; https://orcid.org/0000-0002-2459-5251, Conte, Giulio, Felder, Stefan; https://orcid.org/0000-0002-5029-7274, Huber, Carola; https://orcid.org/0000-0002-2469-0435, Kuehne, Michael, Moschovitis, Giorgio; https://orcid.org/0000-0002-4043-8061, Mueller, Andreas, Paladini, Rebecca E; https://orcid.org/0000-0002-4502-1978, Reichlin, Tobias; https://orcid.org/0000-0002-7197-8415, Rodondi, Nicolas; https://orcid.org/0000-0001-9083-6896, Springer, Anne; https://orcid.org/0000-0002-4829-1041, Stauber, Annina; https://orcid.org/0009-0008-6006-8177, Sticherling, Christian; https://orcid.org/0000-0001-8428-7050, Szucs, Thomas; https://orcid.org/0000-0003-0195-3316, Osswald, Stefan; https://orcid.org/0000-0002-9240-6731, and Schwenkglenks, Matthias; https://orcid.org/0000-0001-7217-1173

Abstract

AIMS Atrial fibrillation (AF) costs are expected to be substantial, but cost comparisons with the general population are scarce. Using data from the prospective Swiss-AF cohort study and population-based controls, we estimated the impact of AF on direct healthcare costs from the Swiss statutory health insurance perspective. METHODS Swiss-AF patients, enrolled from 2014 to 2017, had documented, prevalent AF. We analysed 5 years of follow-up, where clinical data, and health insurance claims in 42% of the patients were collected on a yearly basis. Controls from a health insurance claims database were matched for demographics and region. The cost impact of AF was estimated using five different methods: (1) ordinary least square regression (OLS), (2) OLS-based two-part modelling, (3) generalised linear model-based two-part modelling, (4) 1:1 nearest neighbour propensity score matching and (5) a cost adjudication algorithm using Swiss-AF data non-comparatively and considering clinical data. Cost of illness at the Swiss national level was modelled using obtained cost estimates, prevalence from the Global Burden of Disease Project, and Swiss population data. RESULTS The 1024 Swiss-AF patients with available claims data were compared with 16 556 controls without known AF. AF patients accrued CHF5600 (EUR5091) of AF-related direct healthcare costs per year, in addition to non-AF-related healthcare costs of CHF11100 (EUR10 091) per year accrued by AF patients and controls. All five methods yielded comparable results. AF-related costs at the national level were estimated to amount to 1% of Swiss healthcare expenditure. CONCLUSIONS We robustly found direct medical costs of AF patients were 50% higher than those of population-based controls. Such information on the incremental cost burden of AF may support healthcare capacity planning.

Published
2023

47. Real-World Cost-Effectiveness of Pulmonary Vein Isolation for Atrial Fibrillation: A Target Trial Approach

Author

Serra-Burriel, Miquel; https://orcid.org/0000-0001-8595-1224, Aebersold, Helena; https://orcid.org/0000-0002-4418-9904, Foster-Witassek, Fabienne; https://orcid.org/0000-0002-1631-5838, Coslovsky, Michael; https://orcid.org/0000-0001-7678-7354, Rodondi, Nicolas; https://orcid.org/0000-0001-9083-6896, Blum, Manuel R, Sticherling, Christian; https://orcid.org/0000-0001-8428-7050, Moschovitis, Giorgio; https://orcid.org/0000-0002-4043-8061, Beer, Jürg H; https://orcid.org/0000-0002-7199-0406, Reichlin, Tobias; https://orcid.org/0000-0002-7197-8415, Krisai, Philipp; https://orcid.org/0000-0002-4367-2363, Aeschbacher, Stefanie; https://orcid.org/0000-0001-8134-2421, Paladini, Rebecca E; https://orcid.org/0000-0002-4502-1978, Kühne, Michael; https://orcid.org/0000-0002-2937-3711, Osswald, Stefan; https://orcid.org/0000-0002-9240-6731, Conen, David; https://orcid.org/0000-0002-2459-5251, Felder, Stefan; https://orcid.org/0000-0002-5029-7274, Schwenkglenks, Matthias; https://orcid.org/0000-0001-7217-1173, Serra-Burriel, Miquel; https://orcid.org/0000-0001-8595-1224, Aebersold, Helena; https://orcid.org/0000-0002-4418-9904, Foster-Witassek, Fabienne; https://orcid.org/0000-0002-1631-5838, Coslovsky, Michael; https://orcid.org/0000-0001-7678-7354, Rodondi, Nicolas; https://orcid.org/0000-0001-9083-6896, Blum, Manuel R, Sticherling, Christian; https://orcid.org/0000-0001-8428-7050, Moschovitis, Giorgio; https://orcid.org/0000-0002-4043-8061, Beer, Jürg H; https://orcid.org/0000-0002-7199-0406, Reichlin, Tobias; https://orcid.org/0000-0002-7197-8415, Krisai, Philipp; https://orcid.org/0000-0002-4367-2363, Aeschbacher, Stefanie; https://orcid.org/0000-0001-8134-2421, Paladini, Rebecca E; https://orcid.org/0000-0002-4502-1978, Kühne, Michael; https://orcid.org/0000-0002-2937-3711, Osswald, Stefan; https://orcid.org/0000-0002-9240-6731, Conen, David; https://orcid.org/0000-0002-2459-5251, Felder, Stefan; https://orcid.org/0000-0002-5029-7274, and Schwenkglenks, Matthias; https://orcid.org/0000-0001-7217-1173

Abstract

OBJECTIVES Randomized controlled trials of pulmonary vein isolation (PVI) for treating atrial fibrillation (AF) have proven the procedure's efficacy. Studies assessing its empirical cost-effectiveness outside randomized trial settings are lacking. We aimed to evaluate the effectiveness and cost-effectiveness of PVI versus medical therapy for AF. METHODS We followed a target trial approach using the Swiss-AF cohort, a prospective observational cohort study that enrolled patients with AF between 2014 and 2017. Resource utilization and cost information were collected through claims data. Quality of life was measured with EQ-5D-3L utilities. We estimated incremental cost-effectiveness ratios (ICERs) from the perspective of the Swiss statutory health insurance system. RESULTS Patients undergoing PVI compared with medical therapy had a 5-year overall survival advantage with a hazard ratio of 0.75 (95% CI 0.46-1.21; P = .69) and a 19.8% SD improvement in quality of life (95% CI 15.5-22.9; P < .001), at an incremental cost of 29 604 Swiss francs (CHF) (95% CI 16 354-42 855; P < .001). The estimated ICER was CHF 158 612 per quality-adjusted life-year (QALY) gained within a 5-year time horizon. Assuming similar health effects and costs over 5 additional years changed the ICER to CHF 82 195 per QALY gained. Results were robust to the sensitivity analyses performed. CONCLUSIONS Our results show that PVI might be a cost-effective intervention within the Swiss healthcare context in a 10-year time horizon, but unlikely to be so at 5 years, if a willingness-to-pay threshold of CHF 100 000 per QALY gained is assumed. Given data availability, we find target trial designs are a valuable tool for assessing the cost-effectiveness of healthcare interventions outside of randomized controlled trial settings.

Published
2023

48. Nationwide indoor smoking ban and impact on smoking behaviour and lung function: a two-population natural experiment

Author

Strassmann, Alexandra, Çolak, Yunus, Serra-Burriel, Miquel, Nordestgaard, Børge G, Turk, Alexander, Afzal, Shoaib; https://orcid.org/0000-0002-1442-4694, Puhan, Milo A; https://orcid.org/0000-0001-7284-1317, Strassmann, Alexandra, Çolak, Yunus, Serra-Burriel, Miquel, Nordestgaard, Børge G, Turk, Alexander, Afzal, Shoaib; https://orcid.org/0000-0002-1442-4694, and Puhan, Milo A; https://orcid.org/0000-0001-7284-1317

Abstract

INTRODUCTION Many countries have implemented indoor smoking bans over the past two decades. Although smoking bans have been shown to reduce cardiovascular outcomes, little is known about their impact on respiratory health. This study investigated the impact of a nationwide indoor smoking ban on smoking behaviour and lung function. METHODS We used repeated cross-sectional data from two large cohorts of the general population comprising 31 807 Swiss and 62 093 Danish adults. We compared associations between smoking ban and smoking prevalence and prebronchodilator lung function trends in Denmark (indoor smoking ban introduced in 2007) and Switzerland (indoor smoking ban introduced in 2010) from 2005 to 2010 using a quasi-experimental study design. We performed difference-in-difference analyses with linear regression models adjusted for age, sex, weight and height. RESULTS Denmark had a stronger decrease in active smokers compared with Switzerland. Also, forced expiratory volume in the first second was higher in Danish adults than in Swiss adults: 26 mL (95% CI 2.4 to 49) 1 year, 88 mL (65 to 112) 2 years, and 74 mL (51 to 98) 3 years after smoking ban implementation. Correspondingly, forced vital capacity was higher in Danish adults compared with Swiss adults (80 mL (50 to 109) after 1 year and 126 mL (97 to 155) after two and 3 years). Improvements were observed in both never-smokers and ever-smokers, most pronounced in ever-smokers. CONCLUSIONS Nationwide indoor smoking ban is associated with less smoking and improved lung function in the general population. Implementing an indoor smoking ban can improve lung function by influencing smoking behaviour and reducing secondhand smoke.

Published
2023

49. Patient clusters and cost trajectories in the Swiss Atrial Fibrillation cohort

Author

Aebersold, Helena; https://orcid.org/0000-0002-4418-9904, Serra-Burriel, Miquel, Foster-Wittassek, Fabienne, Moschovitis, Giorgio; https://orcid.org/0000-0002-4043-8061, Aeschbacher, Stefanie; https://orcid.org/0000-0001-8134-2421, Auricchio, Angelo, Beer, Jürg Hans; https://orcid.org/0000-0002-7199-0406, Blozik, Eva, Bonati, Leo H, Conen, David, Felder, Stefan, Huber, Carola A, Kuehne, Michael, Mueller, Andreas, Oberle, Jolanda, Paladini, Rebecca E, Reichlin, Tobias, Rodondi, Nicolas, Springer, Anne, Stauber, Annina, Sticherling, Christian, Szucs, Thomas D, Osswald, Stefan, Schwenkglenks, Matthias, Aebersold, Helena; https://orcid.org/0000-0002-4418-9904, Serra-Burriel, Miquel, Foster-Wittassek, Fabienne, Moschovitis, Giorgio; https://orcid.org/0000-0002-4043-8061, Aeschbacher, Stefanie; https://orcid.org/0000-0001-8134-2421, Auricchio, Angelo, Beer, Jürg Hans; https://orcid.org/0000-0002-7199-0406, Blozik, Eva, Bonati, Leo H, Conen, David, Felder, Stefan, Huber, Carola A, Kuehne, Michael, Mueller, Andreas, Oberle, Jolanda, Paladini, Rebecca E, Reichlin, Tobias, Rodondi, Nicolas, Springer, Anne, Stauber, Annina, Sticherling, Christian, Szucs, Thomas D, Osswald, Stefan, and Schwenkglenks, Matthias

Abstract

Objective: Evidence on long-term costs of atrial fibrillation (AF) and associated factors is scarce. As part of the Swiss-AF prospective cohort study, we aimed to characterise AF costs and their development over time, and to assess specific patient clusters and their cost trajectories. Methods: Swiss-AF enrolled 2415 patients with variable duration of AF between 2014 and 2017. Patient clusters were identified using hierarchical cluster analysis of baseline characteristics. Ongoing yearly follow-ups include health insurance clinical and claims data. An algorithm was developed to adjudicate costs to AF and related complications. Results: A subpopulation of 1024 Swiss-AF patients with available claims data was followed up for a median (IQR) of 3.24 (1.09) years. Average yearly AF-adjudicated costs amounted to SFr5679 (€5163), remaining stable across the observation period. AF-adjudicated costs consisted mainly of inpatient and outpatient AF treatment costs (SFr4078; €3707), followed by costs of bleeding (SFr696; €633) and heart failure (SFr494; €449). Hierarchical analysis identified three patient clusters: cardiovascular (CV; N=253 with claims), isolated-symptomatic (IS; N=586) and severely morbid without cardiovascular disease (SM; N=185). The CV cluster and SM cluster depicted similarly high costs across all cost outcomes; IS patients accrued the lowest costs. Conclusion: Our results highlight three well-defined patient clusters with specific costs that could be used for stratification in both clinical and economic studies. Patient characteristics associated with adjudicated costs as well as cost trajectories may enable an early understanding of the magnitude of upcoming AF-related healthcare costs. Keywords: Atrial Fibrillation; Health Care Economics and Organizations

Published
2023

50. Novel prognostic biomarkers in decompensated cirrhosis: a systematic review and meta-analysis

Author

Juanola, Adrià, Ma, Ann Thu, de Wit, Koos, Gananandan, Kohilan, Roux, Olivier, Zaccherini, Giacomo, Jiménez, César, Tonon, Marta, Solé, Cristina, Villaseca, Clara, Uschner, Frank E, Graupera, Isabel, Pose, Elisa, Moreta, Maria José, Campion, Daniela, Beuers, Ulrich, Mookerjee, Rajeshawar P, Francoz, Claire, Durand, Francois, Vargas, Victor, Piano, Salvatore, Alonso, Sonia, Trebicka, Jonel, Laleman, Wim, Asrani, Sumeet K, Soriano, German, Alessandria, Carlo, Serra-Burriel, Miquel, Morales-Ruiz, Manuel, Torres, Ferran, Allegretti, Andrew S, Krag, Aleksander, Caraceni, Paolo, Watson, Hugh, Abraldes, Juan G, Solà, Elsa, Kamath, Patrick S, Hernaez, Ruben, and Ginès, Pere

Abstract

BackgroundPatients with decompensated cirrhosis experience high mortality rates. Current prognostic scores, including the model for end-stage liver disease (MELD), may underperform in settings other than in those they were initially developed. Novel biomarkers have been proposed to improve prognostication accuracy and even to predict development of complications.MethodsWe performed a systematic review and meta-analysis on novel urine and blood biomarkers and their ability to predict 90-day mortality in patients with decompensated cirrhosis. Secondary outcomes included 28-day and 1-year mortality, and development of acute-on-chronic liver failure, acute kidney injury and other complications. To overcome differences in units, temporal changes in assays and reporting heterogeneity, we used the ratio of means (RoM) as measure of association for assessing strength in predicting outcomes. An RoM>1 implies that the mean biomarker level is higher in those that develop the outcome than in those that do not.ResultsOf 6629 unique references, 103 were included, reporting on 29 different biomarkers, with a total of 31 362 biomarker patients. Most studies were prospective cohorts of hospitalised patients (median Child-Pugh-Turcotte score of 9 and MELD score of 18). The pooled 90-day mortality rate was 0.27 (95% CI 0.24 to 0.29). The RoM for predicting 90-day mortality was highest for interleukin 6 (IL-6) (2.56, 95% CI 2.39 to 2.74), followed by urinary neutrophil gelatinase-associated lipocalin (uNGAL) (2.42, 95% CI 2.20 to 2.66) and copeptin (2.33, 95% CI 2.17 to 2.50). These RoMs were all higher than for MELD (1.44, 95% CI 1.42 to 1.46).ConclusionNovel biomarkers, including IL-6, uNGAL and copeptin, can probably improve prognostication of patients with decompensated cirrhosis compared with MELD alone.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results